SeromYx Systems Announces Strategic Collaboration with University of Pittsburgh to Advance CAR-T Therapy for Solid Tumors

Abigail Harris • September 3, 2025

SeromYx Systems, inc. a global leader in antibody functional profiling services and Systems Serology, is proud to announce a research collaboration with the lab of Dr. Jason Lohmueller, a synthetic biologist at the University of Pittsburgh, aimed at advancing the development of CAR-T therapies for solid tumors.

While CAR-T cell therapy has shown remarkable success in achieving durable remissions in hematologic malignancies, the broader application of this approach including treatment of solid tumors faces substantial limitations due to challenges such as therapeutic resistance from antigen heterogeneity and toxicities.

The Lohmueller lab, located at the UPMC Hillman Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center, is at the forefront of addressing these obstacles through innovative synthetic biology approaches. His team has pioneered the development of “universal” SNAP adaptor CAR and synthetic Notch (synNotch) T cells, offering a modular and programmable platform for more precise and effective targeting of multiple solid tumor antigens with co-administered engineered antibodies (Ruffo et al., Nat Commun, 2023). These cutting-edge technologies promise to overcome many of the barriers that have historically limited the success of adoptive T cell therapy in solid tumors and are licensed for clinical development by Coeptis Therapeutics.

As part of this collaboration, SeromYx is conducting comprehensive biophysical and cellular Fc function profiling of several engineered adaptor antibodies directed against clinically validated solid tumor targets. The company’s Systems Serology platform is being leveraged to evaluate critical immune effector functions and identify optimal antibody-CAR adaptor configurations.

“This collaboration marks an exciting step forward in the pursuit of more effective and accessible CAR-T therapies,” said Lenny Moise, VP, Research at SeromYx Systems. “Dr. Lohmueller’s groundbreaking work in synthetic receptor design is opening entirely new avenues for modular and tunable T cell therapies. By combining our deep expertise in immune profiling with his innovative CAR-T constructs, we aim to generate critical insights that can accelerate the development of next-generation treatments for solid tumors.”

Dr. Lohmueller added, “SeromYx’s cutting-edge immune profiling platform and antibody expertise has already yielded valuable insights into the immunological functions of our adaptor candidates beyond their CAR T activity. These findings are key to guiding our development efforts, and it has been fantastic working with the SeromYx team.”

This partnership exemplifies SeromYx Systems’ ongoing commitment to applying its advanced Systems Serology technologies to enable breakthroughs in translational immunology and the company anticipates that this joint research will contribute to meaningful advances in the field of cancer immunotherapy.

For more information about SeromYx Systems and its pioneering work in Systems Serology services, visit https://www.seromyx.com/.

About SeromYx Systems:

SeromYx Systems is a global leader in providing high-throughput antibody characterization services and Systems Serology, offering advanced solutions for the comprehensive analysis of immune responses. With a dedication to innovation and excellence, and GCLP-accreditation, SeromYx is at the forefront of revolutionizing the fields of translational and clinical immunology through its cutting-edge technologies and strategic collaborations.

Contact:

Abigail Harris

Business Development Manager

abigail.harris@seromyx.com

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

January 21, 2026
The Fc Review: How are antibody developers actually using Fc engineering today? A recent analysis of the IMGT/mAb-DB database takes a systematic look at engineered Fc variants across therapeutic antibodies and fusion proteins, offering a real-world snapshot of how Fc design choices are being deployed in the clinic. Background: Fc engineering is often discussed in terms of individual mutations or isolated use cases. But at an industry level, it’s less clear how frequently Fc variants are used, which functions are prioritized, and whether antibodies rely on single or multiple Fc modifications. By mining curated entries in IMGT/mAb-DB, this study steps back to examine Fc engineering trends across approved and clinical-stage molecules. The review highlights: Fc engineering is widespread across therapeutic antibodies and fusion proteins cataloged in IMGT/mAb-DB Effector silencing strategies are commonly employed, particularly in programs prioritizing safety and controlled immune engagement Many molecules incorporate multiple Fc variants, rather than a single engineered change Fc modifications are used across a range of mechanisms and formats, underscoring Fc’s role as an intentional design lever

Generative design of antibody Fc-variants with synthetic and programmable functional profiles

December 4, 2025
The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. Can we program the Fc region? A recent bioRxiv preprint explores this question at scale, using millions of Fc variants to train machine learning models that predict functional outcomes across FcγR interactions. Background: Through engagement with Fc-receptors, the antibody Fc domain can direct a broad range of immune activities, including phagocytosis, cytokine release, antigen presentation, and immune cell polarization – each of which could be precisely tuned to combat disease. Fc engineering has traditionally focused on modifying one property at a time (E.g., ADCC, ADCP, or half-life). This work instead treats the Fc region as a functional design space and explores how sequence variations across the Fc domain can be linked to real immune engagement. 

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

November 20, 2025
The Fc Review: One Fc variant, three advantages? A Nature Communications study demonstrates how a single Fc-engineered IgG achieved improved half-life, mucosal distribution, and enhanced immune-mediated killing, across both cancer and bacterial models. Background: Fc engineering is often discussed through a single lens, half-life extension, effector boosting, or silencing. This paper explores a broader question: can an Fc variant containing three point mutations deliver multiple functional gains across different biological systems?

Design and engineering of bispecific antibodies: insights and practical considerations

October 28, 2025
The Fc Review: How does Fc engineering shape bispecific antibody function? A Frontiers in Bioengineering and Biotechnology review explores how the Fc region can be tuned to control effector function, half-life, and safety, key levers in the design of next-generation bispecific antibodies ( bsAbs ). Background: Bispecific antibodies bring new therapeutic possibilities by engaging multiple targets at once. But this complexity also brings new challenges, from unwanted immune activation to altered pharmacokinetics . The Fc region plays a central role here, acting as both a stabilizing scaffold and a regulator of immune effector engagement

An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer

October 23, 2025
Abstract: Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding FcγR expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune-engaging antibody design and patient stratification. In this study, we investigated FcR-expressing immune effector cells in HER2 + and triple-negative breast cancers (TNBC), including neoadjuvant chemotherapy–resistant disease. FcγRIIIa expression, FcγRIIIa + NK cells, and classically activated (M1-like) macrophages correlated with improved anti-HER2 antibody efficacy. FcγRIIIa protein and FcγRIIIa + NK cells and macrophages were present in primary TNBC and retained in treatment-resistant tumors.
Text:

Antibody Engineering and Therapeutics 2025

October 10, 2025
Antibody Engineering & Therapeutics 2025

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial

September 15, 2025
Background Authorized COVID-19 vaccines require boosters for continued protection; however, the lack of crossplatform compatible boosters creates practical challenges to keeping populations protected. Methods This Phase 3, multicenter, international, randomized, active-controlled trial compared UB-612 as a thirddose heterologous booster to BNT162b2, ChAdOx1-S, or BBIBP-CorV homologous boosters in healthy subjects aged ≥16 years. Participants were randomly assigned 1:1 to receive a single intramuscular injection of UB-612 or an active comparator matching the primary dose, and were stratified for age, sex, N-protein seropositivity, and time since the last dose of their primary series COVID-19 vaccination. The primary objective was to show noninferiority of neutralizing antibody geometric mean titer (GMT) against live SARS-CoV-2 Wuhan strain after boosting with UB-612 or each of the licensed platform vaccines. Secondary and exploratory objectives covered short and long-term antibody responses. The safety analysis addressed subject and investigator reported adverse events. The study was registered on ClinicalTrials.gov, NCT05293665, and completed on September 12, 2023.

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

September 9, 2025
The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. How does Fc engineering shape the translation of antibodies from preclinical models to the clinic? A new industry-wide review with 15 case studies examines the impact of Fc modifications on pharmacology and safety, and the challenges of predicting human outcomes from nonclinical studies. Background: Fc regions do not only extend half-life, they drive functions like ADCC , ADCP, CDC, and immune modulation. Engineering the Fc can enhance, silence, or redirect these activities. But the same changes that deliver potency can also introduce risk, especially when preclinical models do not fully mirror human Fc receptor biology.

NextGen Biomed 2026

August 25, 2025
NextGen Biomed 2026

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality

August 13, 2025
The Fc Review: Kicking off a new series where we take a closer look at recent Fc-focused papers. What they found, and why it matters for antibody discovery and development. How much does FcγR genetic variation influence an antibody’s function? A recent FDA review examines the often-overlooked role of Fcγ receptor (FcγR) polymorphisms in shaping therapeutic antibody activity, and the implications for the assays used to measure it. Background: FcγRs are the “effector arm” connection between antibodies and immune cells, driving processes like ADCC and ADCP. Genetic variation in these receptors can alter binding strength, modulate effector function, and impact clinical outcomes. Understanding this interplay is important for therapeutic design, potency assessment, and patient response prediction.
More Posts →